FDA Warning for Anti-Seizure Drug Onfi

Elizabeth Davis
Posted on

The FDA recently posted a safety announcement that Onfi (clobazam)—a benzodiazepine used to treat seizures associated with Lennox-Gastaut syndrome—can cause serious and potentially fatal skin reactions.

These reactions are rare, and you should not stop taking Onfi without talking to your healthcare provider; this can cause seizures or other serious withdrawal problems. However, you should stay aware and seek immediate medical treatment if you see any sign of a rash, blistering or peeling of the skin, sores in your mouth, or hives.

The potential skin reactions are called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) and they can occur at any time during your treatment, but it’s most likely that you’ll see a reaction within the first 8 weeks of treatment, or if you stop taking Onfi and then restart.

A warning has also been added to the Onfi drug labeling, and your doctor or pharmacist will be able to discuss any questions or concerns with you.

You can find more information in the complete FDA Safety Announcement.

Drugs featured in this story

Filed under